MARLBOROUGH, Mass.–(BUSINESS WIRE) May 21, 2020 –Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved Kynmobi (apomorphine HCI) sublingual film (APL-130277) for the acute,…Original Article
FDA Approves Kynmobi (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
